mk 0663 has been researched along with Tuberculosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, P; Dyrhol-Riise, AM; Jenum, S; Kristiansen, MP; Kvale, D; Mortensen, R; Mustafa, T; Olsen, IC; Rueegg, CS; Rühwald, M; Røstad, K; Sellæg, K; Taskén, K; Tonby, K | 1 |
| da Cruz, SFS; de Paula Moreira, F; Gadelha, MSM; Lira, YG; Ribeiro, HYU; Sampaio, PCM | 1 |
1 trial(s) available for mk 0663 and Tuberculosis
| Article | Year |
|---|---|
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
Topics: Adolescent; Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Tuberculosis; Tuberculosis Vaccines; Vaccination; Young Adult | 2021 |
1 other study(ies) available for mk 0663 and Tuberculosis
| Article | Year |
|---|---|
Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adrenal Cortex Hormones; Arthritis, Reactive; Carcinoma, Papillary; Etoricoxib; Female; Humans; Isoniazid; Middle Aged; Mycobacterium bovis; Pyridines; Sulfones; Treatment Outcome; Tuberculosis; Urinary Bladder Neoplasms | 2017 |